CNT-DM-01

CNT-DM-01 is a synthetic peptide-based therapeutic candidate being developed by **Centurion Pharma** for the treatment of metabolic disorders, specifically diabetes mellitus. The molecule is part of Centurion's R&D pipeline within the Alimentary & Metabolism category and is formulated for subcutaneous administration via a pen injector. While the specific molecular target is not explicitly disclosed in all pipeline summaries, the "DM" designation and peptide modality strongly suggest it belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class, a standard treatment for type 2 diabetes. Centurion focuses on developing value-added medicines and biosimilars, positioning CNT-DM-01 as a potential alternative to existing GLP-1 therapies in the Turkish and international markets.